Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Viatris And Idorsia Enter Into Significant Global Research And Development Collaboration

Author: Benzinga Newsdesk | February 28, 2024 04:12am

Expands Viatris' Portfolio of Innovative Assets by Immediately Adding Two Phase 3 Assets, Selatogrel and Cenerimod, Both With Blockbuster Revenue Potential
Includes Future Optionality to Expand Collaboration With Additional Innovative Assets
Combines Viatris' Financial Strength and Worldwide Operational Infrastructure With Idorsia's Proven, Highly Productive Drug Development Team and Innovation Engine
Deal Structure Reinforces Viatris' Disciplined Approach to Capital Allocation
Viatris Announces R&D Event to be Held March 27, 2024

Posted In: IDRSF VTRS